. Author manuscript; available in PMC: 2023 Dec 1.

Published in final edited form as: Clin Cancer Res. 2023 Jun 1;29(11):2123–2130. doi: 10.1158/1078-0432.CCR-22-3497

Table 1.

Patient and treatment characteristics for those with NSCLC harboring EGFR E746_A750del vs. L747_A750>P in multi-institution cohort.

	Mutation
Patient Characteristic	E746_A750del (N = 86)	L747_A750>P (N = 36)	P Value

Age at Diagnosis (Median (IQR))	61.5 (54.0 – 69.0)	66.5 (53.5 – 71.5)	0.23
Female	46 (53.5%)	25 (69.4%)	0.10

Asian Race	25 (29.1%)	12 (33.3%)	0.64
Former or current smoking history	30 (34.9%)	11 (30.6%)	0.64

Osimertinib Line of Therapy			0.07

First (1L)	55 (64.0%)	29 (80.6%)

Second or Later (≥2L)	31 (36.0%)	7 (19.4%)